Two cases of cerebrovascular accidents following the induction dose of risankizumab
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | Algün Polat Ekinci, Ahmet Alperen Çevik, Rodi Sari Polat, Fatma Kübra Gül |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
by: A. Bagit, et al.
Published: (2024)
by: A. Bagit, et al.
Published: (2024)
Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis
by: Natalia Rompoti, et al.
Published: (2024)
by: Natalia Rompoti, et al.
Published: (2024)
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
by: Bruce Strober, et al.
Published: (2024)
by: Bruce Strober, et al.
Published: (2024)
Baricitinib and low‐dose prednisone for very severe alopecia areata: A retrospective case series
by: Karen Aouar, et al.
Published: (2026)
by: Karen Aouar, et al.
Published: (2026)
Comments on ‘Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: A nationwide case–control study’
by: Wei‐Min Chu, et al.
Published: (2024)
by: Wei‐Min Chu, et al.
Published: (2024)
De novo pemphigus vulgaris and pemphigus foliaceus development following COVID‐19 infection and vaccination: Matched case–control study
by: P. G. Arduino, et al.
Published: (2024)
by: P. G. Arduino, et al.
Published: (2024)
Personalized dermatologic communication with large language models on high‐stakes personas
by: Ahmet Ugur Atilan, et al.
Published: (2025)
by: Ahmet Ugur Atilan, et al.
Published: (2025)
Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN
by: J. P. Thyssen, et al.
Published: (2024)
by: J. P. Thyssen, et al.
Published: (2024)
Methotrexate for atopic dermatitis: The right dosing and best‐performance administration route
by: A. Nosbaum, et al.
Published: (2025)
by: A. Nosbaum, et al.
Published: (2025)
Erythema dyschromicum perstans following influenza vaccine
by: Sara Al Janahi, et al.
Published: (2024)
by: Sara Al Janahi, et al.
Published: (2024)
Increasing dosing intervals for biologics in atopic dermatitis‐why, who, when and how?
by: M. E. Jacobson, et al.
Published: (2025)
by: M. E. Jacobson, et al.
Published: (2025)
International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study
by: Anouk G. M. Caron, et al.
Published: (2024)
by: Anouk G. M. Caron, et al.
Published: (2024)
International consensus on dose reduction of biologics for patients with psoriasis: The DR . Delphi study
by: C. A. M. van Riel, et al.
Published: (2026)
by: C. A. M. van Riel, et al.
Published: (2026)
Digital dermoscopy follow‐up for acquired longitudinal melanonychia
by: Elvira Moscarella, et al.
Published: (2025)
by: Elvira Moscarella, et al.
Published: (2025)
Annular cutaneous sarcoidosis following COVID‐19 vaccination
by: José Ramos, et al.
Published: (2024)
by: José Ramos, et al.
Published: (2024)
Low‐dose isotretinoin for difficult‐to‐treat rosacea: Enough evidence to be convinced—What's next?
by: Olivier Chosidow, et al.
Published: (2025)
by: Olivier Chosidow, et al.
Published: (2025)
Reply to Hagino et al.: ‘Importance of Upadacitinib dose escalation prior to switch to lebrikizumab’
by: Luigi Gargiulo, et al.
Published: (2025)
by: Luigi Gargiulo, et al.
Published: (2025)
Spironolactone and bicalutamide selectively reduce facial hypertrichosis induced by low‐dose oral minoxidil
by: Juan Jimenez‐Cauhe, et al.
Published: (2025)
by: Juan Jimenez‐Cauhe, et al.
Published: (2025)
Comment on ‘Low‐dose isotretinoin for the management of rosacea: A systematic review and meta‐analysis’
by: Ankur Kapoor, et al.
Published: (2024)
by: Ankur Kapoor, et al.
Published: (2024)
Bridging theory and practice in model‐informed precision dosing of medication in inflammatory skin diseases
by: J. M. P. A. van den Reek, et al.
Published: (2026)
by: J. M. P. A. van den Reek, et al.
Published: (2026)
Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial
by: Ruggero Cascio Ingurgio, et al.
Published: (2026)
by: Ruggero Cascio Ingurgio, et al.
Published: (2026)
Ventilation holes of scabies: Revisiting terminology and physiological context
by: İsmail Hakkı Ünal, et al.
Published: (2025)
by: İsmail Hakkı Ünal, et al.
Published: (2025)
Severe adverse drug reactions induced by lamotrigine: Are prescription guidelines being followed?
by: Alice Thorn, et al.
Published: (2025)
by: Alice Thorn, et al.
Published: (2025)
Reassessing surveillance for longitudinal melanonychia: Insights from digital dermoscopy follow‐up
by: Shiuan‐Chih Chen, et al.
Published: (2025)
by: Shiuan‐Chih Chen, et al.
Published: (2025)
Forehead burns following Ash Wednesday rituals: A retrospective observational analysis
by: Joe Khodeir, et al.
Published: (2025)
by: Joe Khodeir, et al.
Published: (2025)
Pre‐existing psoriasis and immune‐related adverse events following immunotherapy for lung cancer
by: Sydney Corey, et al.
Published: (2026)
by: Sydney Corey, et al.
Published: (2026)
Sustained clinical remission for 5 years in severe epidermolysis bullosa acquisita following rituximab infusions
by: Ben Koszegi, et al.
Published: (2024)
by: Ben Koszegi, et al.
Published: (2024)
GLP‐1RAs and cardiovascular risk in HS: concerns about follow‐up time and effect estimates
by: Beata Jastrząb, et al.
Published: (2025)
by: Beata Jastrząb, et al.
Published: (2025)
AI‐based and LC‐OCT‐guided follow‐up of actinic keratoses under treatment with tirbanibulin 1%
by: Janis Raphael Thamm, et al.
Published: (2024)
by: Janis Raphael Thamm, et al.
Published: (2024)
Does early discontinuation of topical 4% 5‐fluorouracil affect lesion clearance for actinic keratosis? Results from a dose‐ranging study
by: Markus V. Heppt, et al.
Published: (2024)
by: Markus V. Heppt, et al.
Published: (2024)
Cytoreductive approach with hedgehog inhibitors followed by reflectance confocal microscopy assisted Mohs surgery for morpheiform basal cell carcinoma
by: Federico Venturi, et al.
Published: (2024)
by: Federico Venturi, et al.
Published: (2024)
A scoping review of case reports and small case series in Stevens–Johnson syndrome/toxic epidermal necrolysis
by: Mitesh G. Patel, et al.
Published: (2025)
by: Mitesh G. Patel, et al.
Published: (2025)
Impact of light dose and fluence rate on the efficacy and tolerability of topical 5‐ALA photodynamic therapy for actinic keratoses: A randomized, controlled, observer‐blinded intrapatient comparison study
by: Adrian Tanew, et al.
Published: (2024)
by: Adrian Tanew, et al.
Published: (2024)
Flares and new related lesions of Hidradenitis Suppurativa following COVID‐19 vaccination: A retrospective cohort study of 250 patients in Greece
by: Aikaterini I. Liakou, et al.
Published: (2024)
by: Aikaterini I. Liakou, et al.
Published: (2024)
Cowpox—A case of patient‐led diagnosis
by: Neha Ritwik Athalye, et al.
Published: (2025)
by: Neha Ritwik Athalye, et al.
Published: (2025)
Cholinergic pruritus treated with omalizumab: Seven cases
by: Alice Bréhon, et al.
Published: (2024)
by: Alice Bréhon, et al.
Published: (2024)
A case of porokeratosis ptychotropica mimicking condyloma acuminatum
by: Shiyu Jin, et al.
Published: (2025)
by: Shiyu Jin, et al.
Published: (2025)
Secondary laryngeal and pulmonary syphilis: A case report
by: Silvia Borriello, et al.
Published: (2024)
by: Silvia Borriello, et al.
Published: (2024)
Treatment of juvenile localized scleroderma with upadacitinib: A case series
by: Yihan Su, et al.
Published: (2026)
by: Yihan Su, et al.
Published: (2026)
Dupilumab improves skin microbiome in a paediatric case of Netherton syndrome
by: Shota Nakayama, et al.
Published: (2025)
by: Shota Nakayama, et al.
Published: (2025)
Similar Items
-
Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
by: A. Bagit, et al.
Published: (2024) -
Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis
by: Natalia Rompoti, et al.
Published: (2024) -
Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)
by: Bruce Strober, et al.
Published: (2024) -
Baricitinib and low‐dose prednisone for very severe alopecia areata: A retrospective case series
by: Karen Aouar, et al.
Published: (2026) -
Comments on ‘Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: A nationwide case–control study’
by: Wei‐Min Chu, et al.
Published: (2024)